HML Pharmaceuticals Private Limited
About HML Pharmaceuticals Private Limited
Data last updated:
HML Pharmaceuticals Private Limited was a private limited company based in New Delhi, Delhi, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 03 September 2015.
The company was registered with the Registrar of Companies (ROC), Delhi, under CIN U74900DL2015PTC284864. The company has 1 GST registration on record, which is no longer active.
The company had an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It was led by directors Ashish Kumar and Sahib Aggarwal.
Its last annual general meeting (AGM) was held on 29 September 2018, and its latest financial statements are for the year ended 31 March 2018. The registered office was at Plot No. 3G Kh. No. 292 & 293 Ground Floor Kirari Extn. Partap Vihar Phase – I, New Delhi, Delhi, India – 110041.
As per the financials filed for FY 2018, the company reported a revenue of ₹6.26 Lakh, a decline of 91% compared to the previous year. For the same year it recorded a net loss of ₹4.74 Lakh (net margin -75.7%) and EBITDA of -₹4.74 Lakh (EBITDA margin -75.7%).
Company details
Contact details
HML Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressPlot No. 3G Kh. No. 292 & 293 Ground Floor Kirari Extn. Partap Vihar Phase – I, New Delhi, Delhi, India – 110041
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of HML Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of HML Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of HML Pharmaceuticals Private Limited, buy the company report.
Financials of HML Pharmaceuticals Private Limited
FY 2018 filings availableHML Pharmaceuticals Private Limited reported revenue of ₹6.26 Lakh (down 91% YoY) for FY 2018.
Compounded Annual Growth Rate (CAGR)
Revenue fell 91% in the latest year. EBITDA rose 31% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | ₹6.26 Lakh | ||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | -₹4.74 Lakh | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | -₹4.74 Lakh | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | -75.7% | ||
| Net Profit Margin | -75.7% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of HML Pharmaceuticals Private Limited, buy the company report.
Board of directors of HML Pharmaceuticals Private Limited
HML Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashish Kumar | Director | 11 Jul 2017 | 9 Years 3 Months | As last reported |
| Sahib Aggarwal | Director | 03 Sep 2015 | 11 Years 1 Months | As last reported |
Peer comparison
HML Pharmaceuticals Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Albrus Biotec India Private Limited | ₹6.28 Lakh (FY 2022) | -62.0% | Bhopal, Madhya Pradesh, India | |||
| Lezire Pharmaceuticals Private Limited | ₹6.27 Lakh (FY 2019) | 1215.0% | Nagpur, Maharashtra, India | |||
| B.R.R. Pharmaceuticals Private Limited | ₹6.26 Lakh (FY 2025) | -27.0% | Telangana, India | |||
| HML Pharmaceuticals Private Limitedthis company | ₹6.26 Lakh (FY 2018) | -₹4.74 Lakh | -75.7% | -91.0% | New Delhi, Delhi, India |
To see the full peer comparison of HML Pharmaceuticals Private Limited, buy the company report.
Auditor
HML Pharmaceuticals Private Limited is audited by RAJESH SURESH JAIN & ASSOCIATES for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| RAJESH SURESH JAIN & ASSOCIATES | FY 2018 | 017163N |
Shareholding
The shareholding of HML Pharmaceuticals Private Limited is on record for 3 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of HML Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving HML Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for HML Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
HML Pharmaceuticals has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of HML Pharmaceuticals Private Limited, buy the company report.
Recent activity
HML Pharmaceuticals Private Limited has 3 board changes on record since 2015: 2 appointments and 1 cessation. The latest: Anoop Aggarwal ceased to be Director on 17 Jul 2017.
Frequently asked questions
HML Pharmaceuticals has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
HML Pharmaceuticals was a private limited company based in New Delhi, Delhi, India. The company worked in wholesale, within the trading industry. It was incorporated on 03 September 2015 and is registered under CIN U74900DL2015PTC284864. The company has been struck off by the Registrar of Companies and is no longer operational.
HML Pharmaceuticals had 2 directors:
- Ashish Kumar - Director
- Sahib Aggarwal - Director
The CIN (Corporate Identification Number) of HML Pharmaceuticals is U74900DL2015PTC284864. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of HML Pharmaceuticals is at Plot No. 3G Kh. No. 292 & 293 Ground Floor Kirari Extn. Partap Vihar Phase – I, New Delhi, Delhi, India – 110041.
HML Pharmaceuticals was incorporated on 03 September 2015. It is registered with the Registrar of Companies, Delhi.
The latest financial statements of HML Pharmaceuticals on record with the MCA are for the year ended 31 March 2018. Its last annual general meeting was held on 29 September 2018. Year-wise statements from FY 2016 are in the company report.
No. HML Pharmaceuticals has 1 GST registration on record and it is cancelled or inactive.
HML Pharmaceuticals operated in the trading industry, in the wholesale segment. It worked in this industry before it was struck off.
The peers of HML Pharmaceuticals by revenue are Albrus Biotec India Private Limited, Lezire Pharmaceuticals Private Limited, B.R.R. Pharmaceuticals Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading).
Anoop Aggarwal ceased to be Director on 17 Jul 2017. Ashish Kumar was appointed as Director on 11 Jul 2017. Sahib Aggarwal was appointed as Director on 03 Sep 2015.